Q3 2022 Results

2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Company overview Financial review Financial performance References Abbreviations Net debt increased by USD 6.8bn mainly due to dividends and share buybacks, partially offset by FCF (USD bn) -0.9 -7.5 -0.9 -6.8 -7.7 1.1 -7.9 Dec 31, 2021 Dividends M&A transactions Treasury share transactions, net 8.4 Free Cash Flow Others1 Sep 30, 2022 1. Key elements: Currency impact on financial debt and derivative liabilities USD 1.4bn; Payments of lease liabilities USD -0.2bn. 31 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation